Two main approaches in reestablishing normal function of p53 in MM and in cancer in general are based inhibiting the interaction of the protein with its negative regulators (such as MDM2 and MDM4), and on restoring the function of protein product of the mutated TP53 gene (Figure 2). The gene discussed is TP53; the disease is Miyoshi myopathy.